

Hypoglycemia, diabetic medications


Michael Hodgman MD
Upstate New York Poison Center
May 2016

No financial disclosures with
regards this presentation

- Unidentified male in 20s. Driver and only passenger car, struck tree, extensive front end damage, starred windshield.
- Unresponsive, vitals unremarkable (as best I recall!). Large hematoma forehead, no other apparent injury.
- Time of day: mid-afternoon, sunny with dry roads, summer

- 78 yo male brought to ED by EMS with right sided hemiparesis and garbled speech. Family discovered at 18:30, last seen prior 90 minutes earlier. PH: HTN and DM, meds: losartan and glyburide. No ethanol.
- Exam: Awake but apathetic. BP, RR and pulse all normal, T 35.8° C rectally. Neuro exam shows right hemiparesis UE > LE, unintelligible speech.






dextrostick 36 mg/dL

- Today
 - hypoglycemia
 - etiology and management
 - emphasis diabetic medications

Hypoglycemia

- Drugs
 - diabetic medications
 - insulin secretagogues:
quinine
 - interfere with
gluconeogenesis
 - ethanol, salicylates
 - drug interactions
- Other
 - critical illness, starvation
 - fulminant hepatic failure
 - infants and neonates:
inborn error metabolism,
hormonal disturbances
 - insulinoma

Emergency Hospitalizations for Adults ≥ 65 y for adverse drug events



Hypoglycemia

- lab definition: venous glucose \leq 50- 60 mg/dL
 - in neonates: first 24^o as low as 30 mg/dl, first week as low as 45 mg/dL
- symptom defined: adrenergic symptoms, neuroglycopenic symptoms

- Autonomic signs
 - adrenergic: palpitations, tremor, anxiety
 - cholinergic: nausea, sweat, hunger



- Neuroglycopenia
 - confusion, concentration
 - blurred vision
 - behavioral change
 - weakness, fatigue
 - focal weakness
 - seizures, coma

- Unidentified male in 20s. Driver and only passenger car, struck tree, extensive front end damage, starred windshield.
- Unresponsive, vitals unremarkable (as best I recall!). Large hematoma forehead, no other apparent injury.
- Time of day: mid-afternoon, sunny with dry roads, summer

Hypoglycemia

- onset of symptoms hypoglycemia
 - non-diabetics: 55 +/- 2 mg/dL
 - poorly controlled diabetics 77 +/- 5 mg/dL
- tightly controlled diabetics may lose appropriate early warning signs, neuroglycopenia without sympathomimetic warning signs
- long standing diabetes mellitus: loss glucagon response to hypoglycemia and autonomic failure





- A 49 yo male with longstanding IDDM with nephropathy and neuropathy brought to ED following a hypoglycemic episode
- Prehospital FS glucose was < 20 mg/dL, treated 1 amp D50. On arrival to ED he is lethargic and has a repeat dextrostick of 36 mg/dL.
- He receives a 2nd amp D50 with arousal and is given a meal. One hour later his dextrostick is 168 mg/dL.
- Careful interview reveals appropriate use of insulin and normal caloric intake. Despite this, second episode in past week.

141	107	54	20
3,8	25	5,2	

- Insulin clearance
 - hepatic ~60%
 - renal ~ 30%
 - remainder adipocytes, skeletal muscle, placenta

Hypoglycemia

- why did it happen?
 - intentional
 - dose change, double dose
 - visual issues
 - change in renal function
 - concomitant illness
- what are kinetics of product?



Source: Gardner DG, Shoback D: *Greenspan's Basic & Clinical Endocrinology, 9th Edition*: www.accessmedicine.com
Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

Preparation	Onset (SQ administration)	Peak	Duration
lispro, aspart, glulisine	5-15 min	1.5 h	3-4 h
regular	30-60	2 h	6-8 h
NPH	2-4 h	6-7 h	10-20 h
glargine	1.5 h	flat	~ 24 h
detemir	1 h	flat	17 h

- A 37 yo female with Type II DM presents after injecting self with 240 U Lantus at 13:00 and then another 90 U Lantus at midnight.

(Lantus® = glargine)

- Her usual dose?, i.e. insulin resistance?
- One site, multiple site injection?
- Kinetics insulin product
- Her renal function

- Intentional overdose insulin
 - large depot: kinetics different, duration effects may last for days
 - admission, observation
 - initial hypoglycemia following overdose long acting insulin may be delayed, up to 18 h later reported with glargine

- Admission following insulin overdose
 - intentional overdose
 - hypoglycemia following use of longer acting insulin
 - recurrent hypoglycemia after use any insulin product
 - hypoglycemia with renal or hepatic impairment

- Safe for discharge
- accidental extra dose/ double dose
 - euglycemia for 4-6 hours in ED, alert and with good po intake
 - good social support








Figure 1. (Top) Mean serum glucose levels and their 95% confidence intervals with respect to time. (Bottom) Correlation analysis with Pearson's correlation coefficients for *observed* and *expected* changes in serum glucose.

- Adults: 0.5 -1 g/kg D50 (1-2 mL/kg)
- Children: D25, D10
- Toddlers, neonates: D10, 0.2 mg/kg (2 mL D10/kg)
- Hyperosmolar risks:
 - local: phlebitis, thrombophlebitis
 - kids: hyperosmolar coma, neurologic injury

	dextrose per 100 mL	osmolarity
D50	50 g	2,525 mOsm/L
D25	25 g	1,330 mOsm/L
D10	10 g	505 mOsm/L



What about glucagon?


- stimulates gluconeogenesis, glycogenolysis
 - and, beta cells
- prehospital glucagon (1 mg IM) for hypoglycemia
 - mean increase glucose ~ 100 mg/dL
 - improvement mental status ~ 8 minutes
- Dextrose v glucagon prehospital setting
 - recovery to full orientation faster with dextrose (11 min v 28 min)

Be Better
Prepared With

Glucagon




Glucagon for Injection (rDNA origin)
1 mg (1 unit)




Ann Emerg Med 1991;20:375-379

J Accid Emerg Med 1997;14:30-32

- 50 yo male ingests 10 x 5 mg glyburide
- two hours later lethargic, seizure
- dextrose 0.5 g/kg IV prehospital for glucose of 12 mg/dL
- in ED placed on D10 infusion, despite this several more episodes of symptomatic hypoglycemia treated with bolus dextrose with good response, D10 infusion increased






courtesy of Lewis Nelson MD


- glucose induced insulin release from pancreas
- non-diabetics, diabetics with preserved beta-cell function

- antagonism of K efflux channel leads to depolarization of beta cell, opening Ca^{++} channels and release insulin
- beta-cell response response to glucose loading exaggerated with sulfonylurea present



sulfonylurea

octreotide




en.wikibooks.org



Octreotide

- Indication (off label)
 - symptomatic hypoglycemia due to sulfonylurea OD
 - recurrent hypoglycemia unknown etiology
- Dose: 50- 75 ug **SQ** (or IV) q 6 to 8 h
- Duration of action?
 - not well defined for this indication, believed to be about 6-12 hours
- How many doses?
 - in a known sulfonylurea OD 2-3 additional doses should be considered after first dose

	peak	t 1/2	duration action	active metabolites
glipizide	1-3 h	7	12-24 h	no
glipizide_GITS	6-12 h	7	24+ h	no
glyburide	2-6 h	10 h	16-24 h	yes
glimepiride	2-3 h	5-9 h	24+ h	yes



Octreotide

Hypoglycemic episode

- Observation period after last dose octreotide?
 - not well defined, we recommend 12 hours, and:
normally alert and taking po well
- Caveats:
 - massive overdose
 - avoid medically clearing in evening in patient
previously symptomatic

Sulfonylurea ingestion adults

- Intentional overdose: admit
- Naive adult with accidental exposure: admission with observation
 - hypoglycemia onset typically rapid, within hours, nearly all within 6-8 h
 - avoid medically clearing in evening, at night.....
- Adult diabetic with accidental double dose: home management an option **if** good social setting.
 - Greater than double dose, or hypoglycemia: hospital observation

- A 3 yo female maybe ingests a single tablet of ER glipizide
- She arrives in ED 60 minutes post ingestion, alert, happy, playful. Dextrostick 88 mg/dL

- When does hypoglycemia occur post sulfonylurea ingestion in children?
- mean time 4-6 h; exceptional cases delays up to 16-21 h post exposure

Clin Toxicol 1996;34:267-70
J Ped 1997;131:141-46

Sulfonylurea ingestion in children

- We recommend 24 h observation
 - ad lib diet
 - no supplemental dextrose unless hypoglycemia
 - if supplemental dextrose needed, add octreotide

Table 3. Association Between Hospital Admission for Hypoglycemia and Use of Co-trimoxazole in Patients Receiving Glyburide

	No. (%) Exposed		Univariate Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)*
	Cases (n = 909)	Controls (n = 43 766)		
Hospitalization Within 1 Week of Exposure to Second Drug				
Co-trimoxazole	35 (3.9)	189 (0.4)	8.5 (5.8-12.4)	6.6 (4.5-9.7)
Amoxicillin†	10 (1.1)	246 (0.6)	1.8 (1.0-3.5)	1.5 (0.8-2.9)
Hospitalization Within 2 Weeks of Exposure to Second Drug				
Co-trimoxazole	49 (5.4)	319 (0.7)	7.3 (5.4-10.0)	5.7 (4.1-7.9)
Amoxicillin†	13 (1.4)	433 (1.0)	1.4 (0.8-2.5)	1.1 (0.6-2.0)
Hospitalization Within 3 Weeks of Exposure to Second Drug				
Co-trimoxazole	56 (6.2)	447 (1.0)	6.1 (4.6-8.1)	4.9 (3.6-6.6)
Amoxicillin†	19 (2.1)	611 (1.4)	1.5 (0.9-2.3)	1.2 (0.8-1.9)

Abbreviation: CI, confidence interval.

*Multivariate analysis adjusted for factors in Table 1.

†Comparable noninteracting drug for comparison.

Table 3. Association Between Hospital Admission for Hypoglycemia and Use of Co-trimoxazole in Patients Receiving Glyburide

	No. (%) Exposed		Univariate Odds Ratio (95% CI)	Adjusted Odds Ratio (95% CI)*
	Cases (n = 909)	Controls (n = 43 766)		
Hospitalization Within 1 Week of Exposure to Second Drug				
Co-trimoxazole	35 (3.9)	189 (0.4)	8.5 (5.8-12.4)	6.6 (4.5-9.7)
Amoxicillin†	10 (1.1)	246 (0.6)	1.8 (1.0-3.5)	1.5 (0.8-2.9)
Hospitalization Within 2 Weeks of Exposure to Second Drug				
Co-trimoxazole	49 (5.4)	319 (0.7)	7.3 (5.4-10.0)	5.7 (4.1-7.9)
Amoxicillin†	13 (1.4)	433 (1.0)	1.4 (0.8-2.5)	1.1 (0.6-2.0)
Hospitalization Within 3 Weeks of Exposure to Second Drug				
Co-trimoxazole	56 (6.2)	447 (1.0)	6.1 (4.6-8.1)	4.9 (3.6-6.6)
Amoxicillin†	19 (2.1)	611 (1.4)	1.5 (0.9-2.3)	1.2 (0.8-1.9)

Abbreviation: CI, confidence interval.

*Multivariate analysis adjusted for factors in Table 1.

†Comparable noninteracting drug for comparison.

- CYP 2C9 substrate: sulfonylureas
- CYP 2C9 inhibitor: TMP/SMX

JAMA 2003;289:1652-1658

Sulfonylurea related hypoglycemia risk factors

- elderly, esp. with concurrent illness
- recent hospitalization
- poor nutrition
- alcoholism
- renal and liver disease
- polypharmacy

Meglitinides v sulfonylureas

- similar mechanism of action
- rapid onset, short duration action
- published experience limited
- persistent PD effect for 24 h reported with repaglinide overdose in a teenager



Other diabetic medications


- Subtype 2 sodium-glucose transport protein (SGLT2) inhibitors: canagliflozin (Invokana®), dapagliflozin (Farxiga®), empagliflozin (Jardiance®)
 - glycosuria: volume issues

- alpha glucosidase inhibitors: acarbose, meglitol
 - binds intestinal disaccharidases, **nada risk**
- thiazolidinediones (the glitazones, Actos®, Avandia®)
 - acute overdose: limited experience
 - very **unlikely** hypoglycemic risk




GLP-1 agonists (SQ)


1. exenatide
2. liraglutide




GLP-1
glucagon like peptide 1



+




inactivates



DPP-4

dipeptidyl peptidase 4

-



slows gastric
emptying

DPP-4 inhibitors

1. sitagliptin
2. saxagliptin



GLP-1 agonists

1. exenatide
2. liraglutide

Beta cell

GLP-1
glucagon like peptide

releases

DPP-4
dipeptidyl peptidase 4

-
slows gastric
emptying

DPP-4 inhibitors

1. sitagliptin
2. saxagliptin

Observation for 8 hours




- 3 yo male brought to ED lethargic about 20:30. Mom reports child sleepy midafternoon, put him to bed for nap. At 20:00 unable to arouse.
- Unresponsive, smells “minty”. Shortly post arrival suffers grand mal seizure
- Glucose is unmeasurable

- 3 yo male brought to ED lethargic about 20:30. Mom reports child sleepy midafternoon, put him to bed for nap. At 20:00 unable to arouse.
- Unresponsive, smells “minty”. Shortly post arrival suffers grand mal seizure
- Glucose is unmeasurable



Scope original mint mouthwash 15% ethanol



Children: Ethanol and hypoglycemia

- 10 y retrospective review in England, 143 intoxicated children
 - age < 7 y, 10/53 (19%) presented with symptomatic hypoglycemia (blood glucoses 9- 47 mg/dL)
 - age 7- 14 y, 2/90 with symptomatic hypoglycemia
 - selected population (??? true denominator)
- Charity Hospital New Orleans
 - over 4 1/2 years, 3/88 children with a measurable ethanol had a glucose < 67 mg/dL, all were teens (0/8 age < 5 y)

Bariatric surgery and hypoglycemia

- Recent literature on the association of hypoglycemia in bariatric surgery patients, Roux-en-Y procedure in particular
- Typically occurs > 12 months post procedure
- one study with continuous glucose monitoring detected hypoglycemia (≤ 55 mg/dL) in 30/40 over 120 h (do not discuss if/ how often symptomatic.....)
- 29% also with abnormal mixed meal tolerance test

Unexplained hypoglycemia

- suspect covert use insulin or sulfonylurea
 - healthcare worker
 - relative, house mate with diabetes
 - psychiatric history
 - abrupt onset symptoms

Laboratory Investigation

- insulin
- C-peptide
- proinsulin
- anti-insulin antibodies
- sulfonylurea assay (and meglitinides)

Glucometer type	Glucose oxidase method	Glucose Dehydrogenase method
Hypoxemia	falsely increase	falsely increase
galactose xylose, maltose ★ <u>icodextrin</u>		falsely increase
acetaminophen	variable, toxic APAP: may falsely increase significantly	falsely increased, may be significant at toxic concentration
vitamin C (high dose)	variable	falsely increased

Diabetes Care 2007;30:403-409
 Clin Chem 1998;44:893-894
 Am J Clin Pathol 2000;113:75–86

Continuous home glucose monitors




Figure 1—Least squares means and 95% CIs for difference between CGM glucose and BG meter glucose by time point.

1,000 mg dose acetaminophen
false elevation glucose, compared to
glucometer, up to 60+ mg/dL at 2 h









- Ackee fruit, *Blighia sapida*
- Jamacian vomiting sickness
- hypoglycin A, inhibitor of beta oxidation fatty acids, ultimately interferes with gluconeogenesis

Summary

- Insulin/ sulfonylurea intentional overdose: admit
- Naive adults and children with sulfonylurea ingestion: admit
 - adults: at least 8-12 h observation; children 24 h
 - (avoid “clearing” late evening or night)
- Accidental double dose in diabetic, no symptoms, can be managed at home if safe social situation

Summary

- Dextrose is first line antidote
 - sulfonylureas: rebound hypoglycemia with intact beta cells
- Octreotide: low threshold for use with sulfonylurea, meglitinide toxicity; recurrent hypoglycemia unknown etiology